IPO candidate Atara shifts in deal with Memorial Sloan Kettering

IPO-ready Atara Biotherapeutics could license from Memorial Sloan Kettering Cancer Center three treatments already in human clinical trials for certain cancers and persistent viral infections, the company said Tuesday...